Prior early-stage studies in Israel and Canada have already been presented, supporting use as a one-time add-on with standard chemotherapy.
IMPACT now moves into follow-up, with initial results slated for early 2027 to guide pivotal-study design.
Safety profile and treatment approach
Management highlighted a favorable safety profile to date, aiming to keep chemotherapy dosing intact while adding local treatment.
IMPACT pilot study completes enrollment
Alpha Tau Medical completed enrollment in the IMPACT multicenter pilot study of Alpha DaRT with first-line chemotherapy for unresectable pancreatic cancer.
Enrollment expanded from 12 to 48 treated patients, reflecting strong demand and positioning the program for a larger, pivotal trial.
DRTS•
